Edition:
United Kingdom

MorphoSys AG (MORG.DE)

MORG.DE on Xetra

84.35EUR
19 Apr 2018
Change (% chg)

€-2.15 (-2.49%)
Prev Close
€86.50
Open
€85.50
Day's High
€85.85
Day's Low
€84.00
Volume
17,201
Avg. Vol
130,949
52-wk High
€88.40
52-wk Low
€50.50

Chart for

About

MorphoSys AG develops and commercializes antibodies for therapeutic applications. The Company develops drugs using its own research and development, as well as in cooperation with pharmaceutical and biotechnology partners. The Company's operating segments include Proprietary Development and Partnered Discovery. In the Proprietar... (more)

Overall

Beta: 0.78
Market Cap(Mil.): €2,171.58
Shares Outstanding(Mil.): 29.35
Dividend: --
Yield (%): --

Financials

  MORG.DE Industry Sector
P/E (TTM): -- 84.02 32.74
EPS (TTM): -2.61 -- --
ROI: -19.28 1.58 14.38
ROE: -19.78 2.41 16.07

BRIEF-Morphosys Announces Pricing Of IPO Of American Depositary Shares On Nasdaq

* MORPHOSYS ANNOUNCES PRICING OF INITIAL PUBLIC OFFERING OF AMERICAN DEPOSITARY SHARES (ADSS) ON NASDAQ

18 Apr 2018

BRIEF-Morphosys to increase capital to implement Offering Of 8.3 mln ADS

* DGAP-ADHOC: MORPHOSYS RESOLVES A CAPITAL INCREASE TO IMPLEMENT THE OFFERING OF 8,300,000 AMERICAN DEPOSITARY SHARES (ADS) IN THE UNITED STATES

18 Apr 2018

BRIEF-Morphosys AG Sees U.S. IPO 8.3 Mln American Depositary Shares - SEC Filing

* MORPHOSYS AG SEES U.S. IPO 8.3 MLN AMERICAN DEPOSITARY SHARES - SEC FILING

09 Apr 2018

BRIEF-Morphosys Says Tremfya Approved To Treat Psoriasis In Japan

* SAYS ANNOUNCES APPROVAL OF TREMFYA(R) (GUSELKUMAB) FOR THE TREATMENT OF MODERATE TO SEVERE FORMS OF PSORIASIS AND PSORIATIC ARTHRITIS IN JAPAN Source text for Eikon: Further company coverage:

06 Apr 2018

BRIEF-Morphosys AG Files For U.S. IPO Of Up To $150 Mln

* MORPHOSYS AG FILES FOR U.S. IPO OF UP TO $150 MILLION – SEC FILING

22 Mar 2018

BRIEF-Morphosys AG Says ‍Files Registration Statement In United States For A Proposed American Depositary Shares (ADS) Offering​

* SAYS ‍FILES REGISTRATION STATEMENT IN UNITED STATES FOR A PROPOSED AMERICAN DEPOSITARY SHARES (ADS) OFFERING​

22 Mar 2018

BRIEF-Morphosys Sees EBIT Loss Widening To 110-120 Mln Euros In 2018

* ‍REVENUES 2017 UP 34% TO EUR 66.8 MILLION (GUIDANCE EUR 63 TO 66 MILLION)​

13 Mar 2018

BRIEF-Morphosys Announces New Data On Tremfya

* DGAP-NEWS: MORPHOSYS ANNOUNCES THAT TREMFYA(R) (GUSELKUMAB) DATA DEMONSTRATED LONG-TERM SKIN CLEARANCE IN PATIENTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS Source text for Eikon: Further company coverage:

20 Feb 2018

BRIEF-Morphosys And Galapagos Present Results From Phase 1 Study With Mor106

* SAID ON SATURDAY MORPHOSYS AND GALAPAGOS PRESENT RESULTS FROM A PHASE 1 STUDY WITH MOR106 IN ATOPIC DERMATITIS AS LATE-BREAKING ABSTRACT

19 Feb 2018

BRIEF-Galapagos And MorphoSys Present Results From Phase 1 Study With MOR106 In Atopic Dermatitis

* GALAPAGOS AND MORPHOSYS ANNOUNCED ON SATURDAY THAT MOR106 WAS GENERALLY WELL TOLERATED IN ATOPIC DERMATITIS (AD) PATIENTS

19 Feb 2018

Earnings vs. Estimates